In this study of 5,000 women, more women who received Paclitaxel once a week were likely to be alive and free of breast cancer five years after being diagnosed compared to women who received Paclitaxel every three weeks OR women who received Docetaxel (either weekly or every three weeks).

The paper reports final results from a combination REOLYSIN and docetaxel trial, (REO 010) designed to evaluate the anti-tumour effects of systemic administration of REOLYSIN in combination with docetaxel (Taxotere®) in patients with advanced cancer

Apex Drugs & Intermediates Limited, hyderabad is pleased to announce the launch of its newly designed official website